




Bajaj Healthcare Limited

Your Trusted Associate in Pharmaceuticals &
Healthcare Industry



Company Overview





More than **3** decades of
manufacturing expertise



World's Major

Manufacturer of
Chlorhexidine base



India's Major

Manufacturer of Ascorbic Acid



Private Player

Undertaking the Alkaloid Extraction
work for the Government of India




100+

Products manufactured across API
& Intermediates and Formulations



1,500+

Dedicated workforce



20

State-of-the-art
Manufacturing Facilities




100

Finished dosage formulations
manufacturing approval



575+

Client portfolio



60

Total DMF filed



60+

Countries where BHL
has product presence



0.45

Debt/Equity

Mr. Sajankumar R. Bajaj

Chairman & Managing Director

- Self-Driven, dedicated and hard-working leader with over 35+ years of industry experience
- Bachelor's degree in Commerce with business expertise in the field of Finance, Marketing and Material Procurement
- Visionary with an aim to make BHL a well- recognized Indian MNC in the pharmaceuticals and healthcare industry

Mr. Anil C. Jain

Joint Managing Director & Vice Chairman

- Mr. Anil C. Jain is the Vice Chairman as well as Joint Managing Director of the Company. He has completed his diploma in pharmacy.
- Associated with the company for more than 30+ years

Ms. Namrata S. Bajaj

Whole Time Director

- Bachelors in Business Administration from Indian Institution of Planning and Management, Mumbai
- She is associated with the company from more than 10+ years
- Leads the sales and marketing of Formulation division

Mr. Pakshal A. Jain

Whole Time Director

- Latest Addition to the BHL family, Domain Expert in Marketing
- Bachelors in Marketing & Entrepreneurship from India School of Management Entrepreneurship, Mumbai (ISME)
- Keen interest in developing API & Contract Manufacturing

- Our Board consists of well experienced Independent Directors such as Mr. PD Vaghela, retired IAS officer; Mr. Gopalakrishnan Kesavan, distinguished pharmaceutical professional with more than 4 decades of experience; Mr. Ram Banarse, retired assistant commissioner of FDA; Mr. Hemant Karnik, retired Head SME & GM at Saraswat Bank and Mrs. Kejal Shah, experienced Company Secretary.

Management Team

Mr. Rajesh Desai

Financial Advisor

- He brings with him over 37 years of rich and diverse experience across Finance and Legal domains. He has worked with Glenmark Pharmaceuticals. During his tenure, he led the Finance, Legal, and IT functions, playing a pivotal role in driving the company's growth and strengthening its financial foundation.

Mr. Rohan Parekh

Chief Financial Officer

- He is a qualified Chartered Accountant from the ICAI, 2011.
- He holds over 14+ years of expertise and competencies in Corporate Strategy, Investor Relations, Finance and Accounts, Statutory and Internal Audit, FP&A and Treasury fund management.

Mr. Amit Rajan

Chief Technical Officer

- He has over 22 years of global experience in regulatory advisory and quality assurance within the pharmaceutical industry. A Gold Medalist in M.Tech (Analytical Chemistry), he excels in technical and regulatory aspects, with expertise in approvals across key international markets like the EU, US, Canada, Australia, and South Africa. He has successfully managed communications with global regulatory authorities, including FDA, WHO, MHRA, and EDQM.

Mr. Shreekumar Nair

Chief Operating Officer

- He brings over 40+ years of extensive leadership experience in the pharmaceutical industry, having served in senior roles at Alembic and Glenmark. His distinguished career reflects a consistent excellence in operational management, process optimization, and supply chain transformation.

Mr. Nandkumar Soni

Senior Vice President, Operations

- He is a postgraduate in Organic Chemistry from Pune University (1981) with 38 years of experience in synthetic organic chemistry and bulk drug manufacturing. He has worked with reputed pharma companies like IPCA Laboratories, Alembic Pharma, and Boots Pharmaceuticals and has expertise in setting up new API units from the ground up. He has also published research papers in international journals.

Management Team

Mr. AG Prasad

Executive Vice President, Sales & Marketing

- He is an accomplished pharmaceutical sales and marketing leader with 38 years of proven experience. He has worked with leading companies like Makers Labs (IPCA Group) and Glenmark Pharmaceuticals, where he served as Vice President and Cluster Head. At Glenmark, he led four verticals, including Nepal & Bhutan (Rx Market), PAN India Generic-Generic, Corporate Hospitals and Public Health Tender Businesses.

Mr. Dereck Lobo

President, Sales & Marketing

- He has over 40 years of extensive experience at Glenmark across various departments, with a strong focus on procurement and supply chain. He has been with us for the last few years, overseeing the marketing of APIs and Formulations, as well as handling other activities as required.

Mr. E. J. Babu

President, Global Business

- Mr. Babu brings with him 33 years of extensive experience in Global Market. Prior to joining us, he served as the President of Global Business at IPCA Laboratories, where he achieved remarkable growth in both the Global API and Domestic API Business

Mr. Byju T

Vice President, Technical Head

- Mr. Byju brings us 26 years of diversified experience in Pharma Industries, including API process development, Cost improvement, Process Engineering & Technology transfer, Operations & Project portfolio Management, and setting up R&D/API plants from concept to commissioning including multi-purpose API plants. He has also worked on Repurposed drug development(NCE) for new indications including regulatory & project management.
- Prior to joining us, he was associated with Avra Labs (Hyma synthesis), Dai Ichi, Lupin and IPCA Labs.

01

Background

- Commenced operation in the Year 1993, headquartered at Thane, Maharashtra.
- Engaged into manufacturing of Active Pharmaceutical Ingredient (APIs), Intermediates, Finished Dosage Forms & Nutraceuticals.

02

Product Line & capacity

- **730 MT** per month of Active Pharmaceutical Ingredients (APIs) capacity
- **94 MT** per month Intermediates capacity
- **100 Mn** pieces per month Finished Dosage Forms capacity

03

Alkaloid Processing

- BHCL is the private player who has been awarded two contracts by GOI for processing Opium Gum and Poppy Straw
- Constructed new plant that has capacity to process approximately 250 MT of opium gum and about 2500 MT of Poppy straw

04

CDMO Business

- Entered into CDMO Agreement for the supply of 30 new Active Pharmaceutical Ingredients (APIs)' and hold EU approval for the same.

05

Manufacturing Locations

- 18 manufacturing Plants of Active Pharmaceutical Ingredient (APIs) including Intermediate: Tarapur, Maharashtra; Vadodara Gujarat; Panoli, Gujarat.
- 2 Manufacturing Plants of Finished Dosage Forms: Manjusar, Gujarat; Sinnar, Nashik.

06

Major Countries Of Export

- 60+ countries BHL has product presence
- Europe, USA, Australia, Africa, Middle East, South America, Asian Countries, Australia, New Zealand, Sri Lanka, South East Asia, Russia, Korea etc.

07

R&D

- Focus on off – patented APIs Strong R&D Team
- Continues investment in top-of-the-line equipment and technology

08

Formulation

- The Company has initiated various regulatory filings for export of Formulation drugs in ROW Markets.

VISION

- **Our vision** is to be **a leading pharmaceutical company in India** and to become a significant global player by providing high quality and affordable products.
- **Commitment to continuous improvement** and innovation.
- **To develop environment friendly** system.
- **Contributing** towards **better healthcare** through innovation.

MISSION

- Innovation and excellence with customer satisfaction.
- Our mission at Bajaj Healthcare Limited is to become **a significant global player** in manufacturing of APIs and Formulations with high standards of quality and technical services.
- Our mission is to **provide cost-effective products** with reliable quality and delivery within a short span of time.
- To **achieve excellence** in our products and services and to build long term relationships with our customers.

VALUES



Quality and
Competence



Passion for Excellence



Timely Delivery




Performance



Team work

Key Milestones



Our capabilities



Active Pharmaceutical Ingredients (APIs) & Intermediates

- Provide high-quality and high value APIs in key therapeutic categories.
- Focus on producing APIs with Backward Integration.
- Focus on introduction of cutting-edge reverse engineered APIs and amplification of global footprint in this segment.
- Consistently introduced new products under API and invest in development of new process technology, carry out synthetic research and scale up activities
- Portfolio of intermediates which form a key input component for its API and FDF manufacturing, thereby ensuring a steady demand for our products.
- Awarded two contracts by GOI for processing Opium Gum and Poppy Straw at Alkaloid Extraction Plant in Vadodara, Gujarat. Plant Capacity 250 MTPA for Opium Gum and 2500 MTPA for Poppy Straw.

Finished Dosage Formulation (FDFs)

- Manufacture tablets, capsules and powders of Non- Beta lactam therapeutic segments.
- Supply to various Government Institutions across India under tender business
- 100 Mn pieces per month Finished Dosage Forms capacity

CDMO

- The Company has entered into a definitive CDMO agreement with esteemed UK/EU based customers for the supply of 30 Active Pharmaceutical Ingredient (APIs)
- BHL will undertake the development and supply of these molecules, which will be exclusively manufactured for its clientele.
- We are into CDMO sector since 2000, proudly partnering with the third-largest company in Spain.
- We also do contract manufacturing of formulations drugs for reputed Pharma Companies in India.

 Bajaj Oncocare – a dedicated oncology division of Bajaj Healthcare delivering affordable, quality cancer care.

 Focused portfolio across solid tumors, hematological cancers, and supportive care.

 First in India to launch Posaconazole 300 mg, reducing pill burden and improving compliance.

 Robust distribution in 14 States of more than 15 brands ensuring consistent product quality and timely availability.

 Clear roadmap to expand the oncology portfolio nationwide and strengthen patient access across India.

 The Oncology API plant is expected to be ready by 2027

 One section of the Nashik plant is dedicated exclusively for oncology oral dosage formulation

- We are constructing a state-of-the-art peptide manufacturing plant, which is scheduled for commercializing by March 2026. The plant will have an installed capacity of approximately 250 kg per annum, enabling the company to meet both domestic and international demand.
- We have already set up a dedicated R&D peptide synthesis laboratory along with a pilot-scale peptide synthesis facility, strengthening its capabilities across the development lifecycle.
- To date, the R&D team has successfully developed four peptide molecules, and two of these peptides have already been scaled up at the pilot level and total, six peptide molecules are currently under development.
- One of the key products targeted for commercial launch is GLP-1 (Semaglutide), a globally significant peptide molecule widely used as an anti-diabetic medication and increasingly recognized for its weight-loss benefits.
- Bajaj Healthcare is strategically positioned to enter the market with commercial-scale production.

Our Facilities | Certification And Accreditations



API Unit in Savli, GJ

- USFDA approved
- CEP certificate for Chlorhexidine Digluconate solution, Metronidazole Benzoate, Carbamazepine, Oxcarbazepine, Trazodone Hydrochloride, Calcium Dobesilate Monohydrate, Rivaroxaban
- KFDA approved
- TFDA approved
- TGA approved
- Russia approved
- EU-GMP Certificate
- Written Confirmation Certificate.
- HACCP certification
- Star-Kosher certification
- GMP certificate.
- Ecovadis certification.
- Sedex Compliance.
- RSPA certified.
- ISO 9001:2015 certificate
- OK Kosher certification
- FSSC 22K certified
- WHO GMP certified
- Halal certificate



API and Intermediate units in Tarapur MH

- GMP certification by the state FDA for the manufacture of Bulk Drugs/APIs
- ISO 9001:2015 certificate for Manufacture and Supply of Bulk Drugs, Drug Intermediates and Nutraceutical Products.
- Halal certified supply of Bulk Drugs/APIs.
- WHO-GMP certified.



API Unit in Panoli, GJ

- WHO-GMP certified
- ISO 9001:2015 certificate for Manufacture and Supply of Bulk Drugs, Drug Intermediates and Nutraceutical Products.
- Halal certified supply of Bulk Drugs/APIs





Formulation Unit, Manjusar, GJ and Nashik MH

- WHO – GMP certification for the manufacturing of Capsules, Oral Powder and Tablets
- ISO 9001:2015 certificate.



- We have a DSIR-approved R&D facility located within our manufacturing site at Savli, Vadodara, Gujarat.
- Our team consists of more than 50 experienced experts with extensive hands-on knowledge in research and development.
- Within our R&D centre, we focus on new product development, peptide synthesis, and API research.
- In addition, we also carry out formulation development for finished dosage forms.
- To strengthen our R&D leadership, we have appointed Mr. Byju as Senior Vice President. With over 26 years of industry experience, he is leading and overseeing all R&D and ADL activities.
- We are expanding our R&D infrastructure with a new state-of-the-art facility spread across over 10,000 sq. ft. in Savli.
- This upcoming centre will accommodate more than 100 research experts working under one roof and will be equipped with advanced equipments. The facility is expected to be operational by May 2026.



Financials



Profitability Statement

Rs in Cr.

Particulars	FY 2023	FY 2024	FY 2025	HYE Sept 2025
Total Income	647.38	482.10	562.01	299.28
Gross Contribution	264.59	227.33	275.56	145.09
EBITDA	112.95	84.95	101.83	53.99
PBT from Continuing Operations	78.19	27.65	46.01	30.49
Exceptional Item	-	(44.33)	-	-
Tax expense	14.66	(2.34)	3.08	5.86
Profit after Taxes & Exceptional item	63.53	(14.34)	42.93	24.62
Discontinued Operations	(19.97)	(87.18)	(4.01)	(2.24)
Taxation	0.54	(17.72)	(0.58)	(0.56)
Profit after Tax from discontinued operations	(20.51)	(69.46)	(3.43)	(1.68)
Profit for the period	43.02	(83.80)	39.50	22.94

Balance Sheet

Rs in Cr.

Particulars	FY 2023	FY 2024	FY 2025	Sept 2025
Current Assets	509.74	404.54	485.40	472.88
Current Liabilities	115.39	108.60	114.31	105.08
Net Working Capital	394.35	295.94	371.09	367.80
Net Fixed Assets & CWIP	387.40	259.37	241.90	257.02
Other Long Term Assets	4.30	101.20	105.75	108.97
Total Assets	786.05	656.51	718.74	733.79
Total Borrowing	414.33	362.60	237.32	227.87
Other Long Term Liabilities	4.03	15.55	15.26	19.52
Net Worth	367.69	278.36	466.16	486.39

For further information, please contact:

Company :



Bajaj Healthcare Limited

CIN: L99999MH1993PLC072892

Address: 6th Floor, Bhoomi Velocity Infotech Park,
Above ICICI Bank, Road No. 23, Wagle Industrial
Estate, Thane (W) 400 604

THANK YOU